Impact of Sleep Deprivation and Caffeine in Medical Professionals
Exploring the Impact of Sleep Deprivation and Caffeine on Operationally Relevant Complex Cognitive Processes in Medical Professionals
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Silver Spring, Maryland, United States, 20910
- WRAIR Sleep Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Novice group --National Capital Area Interns and Medical Students (3rd and 4th year only)
- Intermediate group - National Capital Area PGY-2 and 3 residents in internal medicine
- Expert group-Board certified internists from National Capital Area
Exclusion Criteria:
Related to Sleep Research Center. The following exclusion criteria apply to all volunteers:
- Self-reported habitual nightly sleep amounts outside the target range of 6-9 hours (i.e., less than 6 hours per night or more than 9 hours per night, on average) (Post-consent Checklist)
- Self-reported nighttime lights-out times earlier than 2100 hours on average during weeknights (Sunday through Thursday) (Post-consent Checklist)
- Self-reported morning wake-up times later than 0900 on average during weekdays (Monday through Friday) (Post-consent Checklist)
- Self-reported habitual napping (> 4 time a week in conjunction with normal sleep habits) (Post-consent Checklist)
- Self-reported caffeine use in excess of 400 mg (e.g., approximately 8 caffeinated sodas or 4 12-oz cups of coffee) per day on average (Post-consent Checklist; document provides exclusionary limits for various caffeinated products).
- Score of lower than 31 or higher than 69 on the Morningness-Eveningness Questionnaire (MEQ form)
- Score of 14 or above on the Beck Inventory Form (BDI form)
- Score of 41 or above on the Spielberger Trait Anxiety Inventory
- History of cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, history of sudden cardiac death or myocardial infarction) (Medical History and Examination Form)
- History of neurologic disorder (to include, but not limited to epilepsy or another seizure disorder, amnesia for any reason, hydrocephalus, MS, narcolepsy or other sleep disorders) (Medical History and Examination form; sleep items on Post-Consent Checklist)
- Underlying pulmonary disease requiring daily inhaler use (Medical History and Examination form)
- Kidney disease or kidney abnormalities (Medical History and Examination form, laboratory results)
- Liver disease or liver abnormalities (Medical History and Examination form, laboratory results)
- Self-reported history of psychiatric disorder requiring hospitalization or psychiatric product for any length of time (Medical History and Examination form)
- Self-reported or suspected regular nicotine use or addiction, defined as more than 1 cigarette or equivalent per week, within the last 1 year (Medical History and Examination form)
- Self-reported or suspected heavy alcohol use; minimum limit to define heavy alcohol use is 14 drinks per week or as determined by the examining study licensed physician (Medical History and Examination form)
- Self-reported or suspected use of products or drugs that cannot be safely discontinued during in-laboratory phases, to be determined on a case-by-case basis by the examining study licensed physician (Medical History and Examination form)
- Self-reported or suspected current use of other illicit drugs, to include but not limited to benzodiazepines, amphetamines, cocaine, marijuana (Medical History and Examination form)
- Positive urine pregnancy result
- Female volunteers who are breastfeeding, lactating, or actively trying to conceive
- Resting blood pressure above 140/90 or resting pulse > 110 (Medical History and Examination form). Note that if a repeat measurement is within range then the volunteer will not be excluded.
- BMI ≥ 30 (Obese Class I or greater) (Medical History and Examination form)
- Clinically significant values (as determined by the reviewing study licensed physician) for any hematology or chemistry parameter. Reviewing physician may opt to repeat any clinically significant tests and include volunteers whose repeat test values are not clinically significant.
- Positive urine nicotine/cotinine result during screening visit (NicCheck™ I test strip results)
- Positive urine drug result during screening visit
- Any use of prescription or over-the-counter sleep aids during the 6 month period prior to screening indicative of a potential sleep disorder as determined by the examining study medical investigator [e.g., use of a sleep aid for several nights following time zone travel, or the occasional use of a sleep inducing medication (e.g. 1-2 times per month), would not necessarily constitute evidence of a sleep disorder and result in disqualification].
- Not fitting into one of four categories: 1) 3rd of 4th year medical student AND native English speaker, 2) medical intern, 3) PGY-2 or PGY-3 resident in internal medicine, 4) board-certified internist (Post-consent checklist)
- Inability to read and sign the consent and HIPAA authorization form
- Active duty military or federal personnel: not off duty and not on approved annual leave for the enrollment visit as well as the in-laboratory phase of the study
Related to FMRI task.
The following exclusion criteria apply to all subjects (MR Safety Screening form):
- The presence of incompatible shrapnel or implanted devices
- A history of prior inability to complete an MRI scan due to anxiety or claustrophobia (participants will not be able to take benzodiazepines or other sedatives prior to the scan to treat anxiety, as these would adversely impact thought processes).
- Being treated with calcium channel blocker medicines (because of the potential impact of such medicines on cerebral blood flow patterns).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Caffeine Group
This group will receive caffeine gum.
|
Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea.
For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum).
Each pellet contains 100 mg of caffeine.
|
|
Placebo Comparator: Placebo
This group will receive gum without caffeine.
|
Pellet form placebo gum
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psychomotor Vigilance Task
Time Frame: 5 days
|
Computer Based response time measurement
|
5 days
|
|
Clinical Reasoning Questions
Time Frame: 5 days
|
Answer clinical board questions
|
5 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Actigraphy
Time Frame: 5 days
|
Wrist movement and activity monitoring
|
5 days
|
|
Polysomnography
Time Frame: 5 days
|
Measurement of brain activity
|
5 days
|
|
Structural Brain Scan-functional MRI
Time Frame: 5 days
|
Measurement of structural brain topography to localize areas of functional activation using a functional MRI scan
|
5 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WRAIR #2311
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.